MRK Articles, Merck & Company Inc. - From 05/28/24

Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage ...

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers struggling to fund late-stage...

In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze compani...

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...

Merck (NYSE: MRK) announced that it is discontinuing a cohort of the phase III study evaluating a co-formulation of its blockbuster PD-L1 inhibitor...

Monday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the&n...

Friday, Aethlon Medical Inc (NASDAQ:AEMD) released results from an in vitro binding study of its Hemopurifier in removing extracellular&n...

The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so fa...

Jim Cramer, the host of CNBC’s “Mad Money,” has warned investors about the current state of the economy and suggested strategies ...

ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrang...